While the DGIdb remains a powerful resource for querying drug–gene interactions, we anticipate future changes that will improve the user experience and the content within it. One change is that claim information will be linked to the licensing terms from constituent sources through the various methods of accessing the DGIdb including the web interface, API endpoints and data downloads. Second, while grouping statistics for claims have improved in the DGIdb 3.0, there are still a significant percentage of claims that remain ungrouped. To address this, the drug grouper will need to be optimized to handle the exceptions that currently prevent successful grouping. Third, much of the user interface is a series of static renders by the server. A potential future enhancement is a more reactive, client-side web application that would allow for more dynamic visualization and exploration of the data. Finally, other databases (e.g. CIViC) have had success utilizing a community curation model. In an effort to enable community feedback to address the complexity of grouping and representing drug–gene interaction data, the DGIdb will be moved to a similar model.
